Create What You Wish Existed in Cancer Care

The Indigo Imperative

I design many years hence when oaks are more valueable than they are now—which you know they will be when we come to build fleets.” 

—Eliza Lucas Pinckney, letter to Miss Bartlett, ca. May 1742

Image From: An Illustrated Biography of Eliza Lucas Pinckney, Planter & Patriot ~ written & illustrated by Dianne Coleman

In the intricate ecosystem of modern cancer care—where oncologists navigate evolving treatment paradigms, pharmaceutical leaders decode regulatory complexities, and AI scientists chase algorithmic breakthroughs—we inhabit a moment of profound contradiction. Never have we possessed more formidable weapons against malignancy: genomic sequencing that deciphers tumor DNA in hours, immunotherapies that transform patients’ own T-cells into precision-guided missiles, machine learning models that predict drug responses with startling accuracy.

Yet the gaps yawn wider than ever. We witness them daily: the patient whose optimal therapy exists but remains inaccessible due to geographic lottery, the biomarker discovery that languishes in academic silos while patients receive suboptimal care, the health disparities that render molecular precision meaningless for entire populations. These fractured journeys, data silos, and systemic inequities are not merely operational failures. They are creative opportunities disguised as problems.

Here lies our paradox. Despite endless conferences about disruption and transformation, many of us remain spectators to change rather than architects of it. We wait for the perfect platform to emerge from Silicon Valley, for the ideal protocol to survive clinical validation, for someone else to build the thing we desperately wish existed. We have become curators of possibility rather than creators of reality.

The Creative Code Within

The chronicle of human advancement reads like a catalog of absences made manifest. Every breakthrough—from Röntgen’s serendipitous X-ray discovery to the first CAR-T cell therapy—began as a void, an absence that existed only in the imagination of those audacious enough to envision what could be.

In molecular biology, we recognize this as gene expression. A gene may lie dormant within cellular architecture for years, its transformative potential encoded but silenced, until environmental signals trigger its transcription into functional reality. The creative capacity within each of us operates similarly. It is a latent genetic program waiting for the right conditions to express itself into innovation.

But this creative gene often remains unexpressed, inhibited by powerful suppressor mechanisms. There is the gravitational pull of established systems, the seductive comfort of incrementalism that renders radical creation seemingly unnecessary. There is the paralysis of perfectionism, the psychological weight of investing expertise and reputation into something that might fail spectacularly. Most insidious is the mythology of genius. It is the quiet conviction that transformative building belongs to others, to the celebrated innovators whose stories we consume with admiration but never internalize as templates for our own action.

History, however, tells a different story.

The Plantation Laboratory

Consider Eliza Lucas Pinckney, whose name appears in no pantheon of medical pioneers yet whose approach to innovation offers a masterclass in creative courage. In 1740s South Carolina, rice ruled absolutely. It was the colony’s economic lifeblood, its agricultural identity, its path to prosperity. But this monoculture harbored profound fragility, vulnerable to climate variations and volatile international markets.

Into this environment stepped sixteen-year-old Eliza, inheriting management of her father’s three plantations while he served as Lieutenant Governor of Antigua. Where others saw only the established rhythm of rice cultivation, she perceived systemic risk. Where conventional wisdom demanded conformity to proven methods, she envisioned radical diversification.

Her target was indigo. The tropical plant produced the deep blue dye commanding premium prices across European markets. Her father had sent seeds and cultivation notes, but no precedent existed for such agricultural entrepreneurship, especially by a young woman in a rigidly hierarchical society. The conventional path lay clear: manage existing systems, optimize known processes, avoid unnecessary risk. The creative path remained uncharted: build something entirely new.

The Architecture of Persistent Action

Pinckney’s genius manifested not in flash intuition but in systematic bias toward action. She refused to wait for perfect conditions or formal permission. When her father’s tropical indigo strains failed repeatedly in Carolina’s alien soil, she treated each failure as data rather than defeat. Her laboratory was not a facility but her own methodical mind, documenting variables with scientific precision: soil composition, planting depths, irrigation schedules, seasonal timing.

Each negative result became a hypothesis for the next iteration. This represents the fundamental principle of innovation in any complex system: the willingness to begin with incomplete information and allow experimentation to refine understanding. Every failed clinical trial in oncology, every diagnostic tool that doesn’t achieve projected sensitivity, every patient navigation program that falls short. These are not indictments of futility but essential data points in the larger experiment of advancing care.

Her approach reveals the antidote to the imposter syndrome that paralyzes so many potential healthcare innovators. Pinckney faced withering skepticism from seasoned planters who dismissed her project as folly. Yet her conviction rested not on abstract confidence but on empirical foundation. She had researched the plant, studied market dynamics, tested methodologies systematically. When you have truly done the work—when you’ve transformed intuition into rigorous process—you’re no longer operating on sentiment but on data, on the irrefutable evidence of methodical effort.

Strategic Collaboration as Force Multiplier

Beyond individual persistence, Pinckney’s breakthrough illuminates the critical role of intentional networking in complex innovation. She understood that her considerable knowledge remained incomplete. Her decisive advance came through actively seeking an elderly French indigo master, inviting him to her plantation and compensating him to teach the intricate dye extraction process.

This wasn’t passive relationship-building but surgical collaboration driven by mutual value creation. Pinckney’s networking was precise. She identified the specific expertise holder who possessed her missing piece and structured an exchange that served both parties. Her model offers a powerful template for today’s cancer care innovators: the knowledge you need often exists, but accessing it requires deliberate search and the courage to share your vision with strategic strangers.

Think of the clinical oncologist who partners with the bioinformatics team to create the treatment selection algorithm that doesn’t yet exist. The pharmaceutical researcher who collaborates with the health equity advocate to design trials that actually reflect patient populations. The diagnostic company executive who works with the community oncology practice to build the point-of-care testing platform that could transform rural cancer care. Each represents Pinckney’s model: targeted collaboration to unlock breakthrough innovation.

The Multiplication Imperative

Pinckney’s success transcended personal achievement. Rather than hoarding her breakthrough, she distributed seeds to other planters and published cultivation methods, creating a thriving industry that flourished across the South for decades. She understood that innovation’s ultimate value lies not in exclusivity but in its capacity to become foundation for others’ building.

This principle resonates powerfully across today’s cancer care ecosystem. The AI algorithm that helps one health system identify high-risk patients earlier becomes exponentially valuable when shared across networks. The patient engagement platform that reduces treatment delays in urban centers creates multiplying impact when adapted for rural populations. The biomarker discovery that improves outcomes in one cancer type often holds keys to advances across multiple malignancies.

The greatest innovations in oncology have always enabled broader innovation rather than capturing it. Consider how the development of monoclonal antibody technology didn’t create one breakthrough therapy but an entire class of targeted treatments. How next-generation sequencing didn’t solve one diagnostic challenge but revolutionized precision medicine across multiple diseases.

Your Indigo Moment

Today, in cancer care, we face our own South Carolina moment. We have our rice: established treatment protocols, traditional care delivery models, familiar technologies that work but leave vast territories of possibility unexplored. We also have our potential indigo everywhere: precision medicine approaches still nascent, AI applications barely scratched, patient experience innovations existing only as PowerPoint concepts, health equity solutions trapped in academic papers rather than operational reality.

The opportunities are not hidden. They announce themselves daily. The clinical decision support tool you wish existed when choosing between treatment options. The patient portal that actually serves patients rather than administrators. The diagnostic pathway that eliminates the delays you know cost lives. The partnership model that finally bridges academic medicine and industry innovation. The community outreach program that could catch cancers earlier in underserved populations.

The Urgency of Now

This moment in cancer care history demands more than incremental improvement. The field is being reimagined from its molecular foundations to its delivery systems, from financing models to regulatory frameworks. Immunotherapy is rewriting treatment paradigms. Artificial intelligence is transforming diagnostic accuracy. Liquid biopsies are enabling earlier detection. Telemedicine is expanding access to expertise.

Those who wait for permission, for perfect conditions, for someone else to go first, will find themselves spectators to transformation rather than architects of it. The patients whose lives could be changed by your innovation are not waiting for ideal circumstances to need better care. They need it now, with the tools and knowledge available today.

The Call to Create

The creative gene within you contains not just the capacity to build but the responsibility to build. Your unique vantage point—whether as a clinician frustrated by treatment delays, a researcher seeing patterns others miss, an industry leader understanding market dynamics, or a technologist envisioning new applications—gives you insights that no one else possesses.

Like Pinckney, you don’t need perfect conditions to begin. You need to start with what you have, learn from what doesn’t work, and persist through the inevitable setbacks that separate dabbling from creation. You need to trust not in abstract self-confidence but in your willingness to do the methodical work of turning vision into reality.

The thing you wish existed in cancer care—that diagnostic tool, that treatment protocol, that patient support system, that data integration platform—is waiting not for someone else to build it but for you to express your creative potential. The patients whose outcomes could be transformed by your innovation are counting on creators, not critics.

Consider Pinckney’s indigo, how it colored not just fabric but an entire economy, creating prosperity that extended far beyond her plantation. Your innovation in cancer care could color lives with hope, extend survival, improve quality of life, reduce disparities, accelerate discoveries. But only if you choose to plant the seeds.

The time for building is not someday when conditions are perfect. It is today, with the imperfect tools and incomplete knowledge at hand. The person to build it is not the mythical innovator you imagine doing the work. It is you.

What is your indigo? What will you create?

The patients are waiting. History is watching. Your creative gene is ready for expression.

Begin.